Summary by Moomoo AI
ZyVersa Therapeutics, Inc. has announced that starting March 27, 2024, Morrow Sodali LLC, the company's proxy solicitors, will disseminate an audio recording from the Chief Financial Officer, Peter Wolfe, to certain stockholders. The communication is part of the preparations for the upcoming 2024 Special Meeting of Stockholders scheduled for April 17, 2024. In the recording, Wolfe discusses the current biotech environment, characterized by low valuations and reduced capital availability, and outlines the company's strategy to navigate these challenges. One of the strategies mentioned is a potential reverse stock split to maintain compliance with Nasdaq's listing requirements and to make the stock more attractive to new investors. However, Wolfe expresses hope that this measure will not be necessary, citing increased investor confidence due...Show More